Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.
Albert Muñoz-VendrellPablo Arroyo-PereiroIsabel LeónLaura BauElisabet MatasAntonio Martínez-YélamosSergio Martínez-YélamosLucía Romero-PinelPublished in: Journal of neurology (2023)
The JCV status can be used as a natural experiment to compare treatment arms with a low selection bias. In our study, switching to OCR versus NTZ continuation led to similar disease activity outcomes.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- rheumatoid arthritis patients
- newly diagnosed
- ejection fraction
- multiple sclerosis
- ankylosing spondylitis
- chronic kidney disease
- peritoneal dialysis
- juvenile idiopathic arthritis
- type diabetes
- skeletal muscle
- patient reported